FDA Approval for MARGENZA

12/20/20 4:31:01 PM ET

$MGNX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MGNX alert in real time by email

Biologic License Application (BLA): 761150
Company: MACROGENICS INC

Products on BLA 761150

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
MARGENZA	MARGETUXIMAB-CMKB	250MG/10ML(25MG/ML)	INJECTABLE;INJECTION	Prescription	None	TBD	No

Approval Date(s) and History, Letters, Labels, Reviews for BLA 761150

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
12/16/2020	ORIG-1	Approval		N/A		Label is not available on this site.

Get the next $MGNX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MGNX

Date	Price Target	Rating	Analyst
8/1/2024		Buy → Neutral	BTIG Research
7/31/2024	$18.00 → $5.00	Buy → Neutral	B. Riley Securities
7/31/2024		Buy → Neutral	Guggenheim
5/10/2024	$24.00 → $8.00	Outperform → Market Perform	BMO Capital Markets
5/10/2024	$29.00 → $7.00	Buy → Hold	Stifel
5/10/2024		Buy → Hold	TD Cowen
4/26/2024	$25.00	Buy	B. Riley Securities
4/9/2024		Hold → Buy	TD Cowen

More analyst ratings

MacroGenics Announces Leadership Transition
Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company's Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the t
10/30/24 7:30:00 AM ET
$MGNX
Biotechnology: Pharmaceutical Preparations
Health Care
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 5, 2024, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance via this link. Upon registration, all telephone participants will receive a
10/29/24 4:30:00 PM ET
$MGNX
Biotechnology: Pharmaceutical Preparations
Health Care
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain management, announced today that they have entered into an agreement in which TerSera will acquire global rights to MARGENZA® (margetuximab-cmkb). MARGENZA was approved by the U.S. Food and Drug Administration (FDA) in December 2020 in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior
10/22/24 7:30:00 AM ET
$MGNX
Biotechnology: Pharmaceutical Preparations
Health Care

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 5, 2024, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance via this link. Upon registration, all telephone participants will receive a
10/29/24 4:30:00 PM ET
$MGNX
Biotechnology: Pharmaceutical Preparations
Health Care
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of treatment duration as compared to Phase 1 mCRPC dose expansion cohortCompany expects to have mature median rPFS no later than early 2025MacroGenics to host an investor call to review key data presented at ESMO and provide a general corporate update on Monday, September 16, 2024, at 8:00 a.m. ET ROCKVILLE, MD, Sept. 15, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing
9/15/24 3:00:00 AM ET
$MGNX
Biotechnology: Pharmaceutical Preparations
Health Care
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced a poster presentation relating to Phase 2 data of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain from September 13-17, 2024. The following poster will be available on Sunday, September 15, 2024: TAMARACK: Randomized Phase 2 trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitam
9/8/24 7:10:00 PM ET
$MGNX
Biotechnology: Pharmaceutical Preparations
Health Care

MacroGenics Announces Leadership Transition
Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company's Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the t
10/30/24 7:30:00 AM ET
$MGNX
Biotechnology: Pharmaceutical Preparations
Health Care
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A. Liu and Meenu Chhabra Karson to its Board of Directors, effective January 3, 2023. Dr. Liu will serve as a member of MacroGenics' Science and Technology Committee and Ms. Karson will serve as a member of the Company's Audit Committee. Following the appointment of Dr. Liu and Ms. Karson, MacroGenics' Board will comprise ten directors, nine of whom are independent. "We are delighted to have both Margaret and Meenu join Ma
1/4/23 4:30:00 PM ET
$MGNX
Biotechnology: Pharmaceutical Preparations
Health Care
MacroGenics Announces Appointment of William Heiden to Board of Directors
ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of William Heiden to its Board of Directors, effective May 22, 2022. Mr. Heiden will serve as Chair of the board and a member of the Audit Committee. Following the appointment of Mr. Heiden, the Board will comprise eight directors, seven of whom are independent. Mr. Heiden is replacing Paulo F. Costa as Chair. Mr. Costa served in the Chair position until his term as director expired on May 19, 2022. "We are delighted to have Bill join Macr
5/23/22 4:01:00 PM ET
$MGNX
Biotechnology: Pharmaceutical Preparations
Health Care

$MGNX
Market Insights

Live Market Insights

Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results. SAIC reported a 9% revenue decline year over year in the fiscal first quarter of 2025 to $1.847 billion, marginally beating the analyst consensus estimate of $1.844 billion. Adjusted EPS of $1.92 was in line with the analyst consensus estimate, according to data from Benzinga Pro. SAIC shares dipped 11% to $119.91 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Microbot Medical Inc. (NASDAQ:MBOT) jumped 92.5% to $1.9301 after the company received FDA approval to proceed with its pivotal human clinical trial. Bio-Pa
6/3/24 1:56:53 PM ET
$ADRT
$ADSK
$AFMD
$AMC
Blank Checks
Finance
Computer Software: Prepackaged Software
Technology
Demystifying Macrogenics: Insights From 14 Analyst Reviews
Analysts' ratings for Macrogenics (NASDAQ:MGNX) over the last quarter vary from bullish to bearish, as provided by 14 analysts. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 6 4 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 3 0 0 2M Ago 0 0 0 0 0 3M Ago 3 4 1 0 0 In the assessment of 12-month price targets, analysts unveil insights for Macrogenics, presenting an average target of $17.57, a high estimate of $29.00, and a low estimate of $4.00. Highlighting a 7.18% decrease, the current aver
5/24/24 2:00:53 PM ET
$MGNX
Biotechnology: Pharmaceutical Preparations
Health Care
BTIG Maintains Buy on Macrogenics, Lowers Price Target to $9
BTIG analyst Kaveri Pohlman maintains Macrogenics (NASDAQ:MGNX) with a Buy and lowers the price target from $24 to $9.
5/24/24 1:02:20 PM ET
$MGNX
Biotechnology: Pharmaceutical Preparations
Health Care

FDA Approval for MARGENZA

Products on BLA 761150

Approval Date(s) and History, Letters, Labels, Reviews for BLA 761150

Original Approvals or Tentative Approvals

Chat with this insight

Recent Analyst Ratings for $MGNX

$MGNX SEC Filings

SEC Form 8-K filed by MacroGenics Inc.

MacroGenics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

MacroGenics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$MGNX Press Releases

Fastest customizable press release news feed in the world

$MGNX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

MacroGenics Announces Leadership Transition

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

MacroGenics downgraded by BTIG Research

MacroGenics downgraded by B. Riley Securities with a new price target

MacroGenics downgraded by Guggenheim

$MGNX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by MacroGenics Inc.

SEC Form SC 13G filed by MacroGenics Inc.

SEC Form SC 13G/A filed by MacroGenics Inc. (Amendment)

$MGNX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President and CEO Koenig Scott gifted 53,265 shares and received a gift of 53,265 shares, closing all direct ownership in the company (SEC Form 4)

President and CEO Koenig Scott gifted 374,215 shares and received a gift of 374,215 shares, decreasing direct ownership by 35% to 703,413 units (SEC Form 4)

SEC Form 4 filed by Liu Margaret (Amendment)

$MGNX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for MARGENZA issued to MACROGENICS INC

FDA Approval for MARGENZA

$MGNX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Biotech Target N V bought $669,585 worth of shares (150,000 units at $4.46), increasing direct ownership by 2% to 9,929,963 units (SEC Form 4)

$MGNX Financials

Live finance-specific insights

$MGNX Leadership Updates

Live Leadership Updates

MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call

MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024

MacroGenics Announces Leadership Transition

MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

MacroGenics Announces Appointment of William Heiden to Board of Directors

$MGNX Market Insights

Live Market Insights

Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Demystifying Macrogenics: Insights From 14 Analyst Reviews

BTIG Maintains Buy on Macrogenics, Lowers Price Target to $9

Recent Analyst Ratings for
$MGNX

$MGNX
SEC Filings

$MGNX
Press Releases

$MGNX
Analyst Ratings

$MGNX
Large Ownership Changes

$MGNX
Insider Trading

$MGNX
FDA approvals

$MGNX
Insider Purchases

$MGNX
Financials

$MGNX
Leadership Updates

$MGNX
Market Insights